What Is Liver Cancer?

Liver cancer is a malignant disease that originates in the tissue of the liver, most often in the hepatocytes that perform the organ's metabolic and detoxification work. The dominant form is hepatocellular carcinoma, which accounts for roughly three quarters of primary liver tumors worldwide. Intrahepatic cholangiocarcinoma, arising from the epithelium of the bile ducts, makes up most of the remainder, with hepatoblastoma and angiosarcoma appearing far less frequently. Primary liver cancer is distinguished from metastatic liver disease, in which tumors that began in the colon, pancreas, or breast colonize the liver, because the two are staged, imaged, and treated along different lines.

The disease is unusual among solid tumors in that it almost always develops against a background of chronic liver injury rather than in healthy tissue. Cirrhosis from any cause raises risk sharply, and chronic hepatitis B and hepatitis C infection, heavy alcohol use, aflatoxin exposure, and metabolic dysfunction associated steatotic liver disease are the principal drivers identified in the National Cancer Institute's summary of liver cancer risk factors. Because the population at risk is largely known in advance, liver cancer has become a testing ground for surveillance imaging, computational risk scoring, and image-guided intervention.

Carcinogenesis and Risk Stratification

Repeated cycles of hepatocyte death, inflammation, and regenerative proliferation create the genomic instability from which hepatocellular carcinoma emerges. Hepatitis B virus adds a second mechanism by integrating its DNA into the host genome, which is why it can produce tumors even without established cirrhosis. Epidemiological work summarized in a review of hepatocellular carcinoma incidence and risk factors traces the sharp geographic gradient in disease burden to the distribution of viral hepatitis, with East Asia and sub-Saharan Africa carrying incidence rates several times those of North America and Western Europe. Risk models combining age, sex, viral load, platelet count, and fibrosis stage are used to decide who enters semiannual ultrasound surveillance.

Imaging and Diagnosis

Liver cancer is one of the few malignancies that can be diagnosed without a biopsy. Multiphase contrast-enhanced computed tomography and magnetic resonance imaging capture a characteristic pattern of arterial phase hyperenhancement followed by washout in the portal venous or delayed phase, a signature produced by the tumor's shift toward arterial blood supply. The Liver Imaging Reporting and Data System codifies this pattern into standardized categories, and serum alpha-fetoprotein provides a complementary if imperfect biomarker. Clinical reference material such as the StatPearls overview of hepatocellular carcinoma sets out how these findings combine with the Barcelona Clinic Liver Cancer staging system to select treatment. Radiomics and convolutional neural network models are now applied to the same image series to flag lesions that a reader might miss on a screening ultrasound.

Treatment and Image-Guided Intervention

Treatment depends on tumor burden and on how much functional liver remains. Surgical resection and liver transplantation offer cure for early localized disease. For intermediate cases, interventional radiology supplies a set of catheter and needle based options: radiofrequency and microwave ablation, transarterial chemoembolization, and transarterial radioembolization with yttrium-90 microspheres. Each of these depends on real-time image guidance, thermal or dosimetric modeling, and precise catheter navigation. Advanced disease is managed systemically, increasingly with combinations of immune checkpoint inhibitors and antiangiogenic agents, and stereotactic body radiation therapy provides a noninvasive alternative where ablation is not feasible.

Applications

Liver cancer research and care draw on a range of technical disciplines, including:

• Medical imaging, including contrast-enhanced CT, MRI, and ultrasound elastography
• Machine learning for lesion detection, segmentation, and prognosis
• Interventional device engineering for ablation probes and embolization catheters
• Radiation dosimetry and treatment planning
• Biosensors and assay design for circulating tumor DNA and protein biomarkers
• Public health informatics for hepatitis screening and vaccination programs